Les incontournables

Santé mondiale et recommandations

• WHO global report on hypertension 2025..Farrar J, Frieden T. Lancet. 2025 Nov 15;406(10517):2318-2319. Lire
• Global, regional, and national burden of chronic kidney disease in adults, 1990-2023, and its attributable risk factors: a systematic analysis for the Global Burden of Disease Study 2023. GBD 2023 Chronic Kidney Disease Collaborators. Lancet. 2025 Nov 7:S0140-6736(25)01853-7. Lire
• Role of Circadian Health in Cardiometabolic Health and Disease Risk: A Scientific Statement From the American Heart Association.Knutson KL, et al. Circulation. 2025 Oct 28. Lire

Revues

• Renal Histology Findings in Malignant Hypertension, a Systematic Review. Maisons V, et al.Hypertension. 2025 Nov 4. Lire

Etudes de cohorte

• Blood pressure variability is associated with heart failure risk, elevated NT-proBNP, and elevated high-sensitivity troponin: the Multi-Ethnic Study of Atherosclerosis (MESA). Nuyujukian DS, et al. Am J Hypertens. 2025 Nov 14:hpaf226. Lire
• Hypertension in Young Adults: Social Determinants of Prevalence, Awareness, Treatment, and Control. Alexander TJ, et al. Am J Hypertens. 2025 Nov 13:hpaf203. Lire
• Renal Denervation in Patients With Moderate to Severe Chronic Kidney Disease. Schlaich MP, et al. Hypertension. 2025 Oct 29. Lire

Post-Hoc de l’étude SPRINT

• Relationship Between Home Blood Pressure Monitoring-Confirmed Resistant Hypertension and Cardiovascular Prognosis Kario K, et al. Hypertension. 2025 Oct 23. Lire
• Effect of Intensive Systolic Blood Pressure Control on Markers of Cerebral Small Vessel Disease by Age.Pruzin JJ, et al. Hypertension. 2025 Oct 29. Lire

Essais cliniques

• DASH-Patterned Groceries and Effects on Blood Pressure: The GoFresh Randomized Clinical Trial.Juraschek SP, et al.JAMA. 2025 Nov 9:e2521112. Lire

Recherche Fondamentale

• Identification and Characterization of Alamandine-(1-5), a New Component of the Renin-Angiotensin System. Santos RAS, et al. Circ Res. 2025 Nov 12. Lire

Clinical trials

• Efficacy of olive leaf extracts in controlling blood pressure in hypertensive patients: a double-blind randomized clinical trial.Lamti F, et al.J Hypertens. 2025 Nov 1;43(11):1878-1884. doi: 10.1097/HJH.0000000000004141 LIRE
• Efficacy and Safety of Baxdrostat in Uncontrolled and Resistant Hypertension. Flack JM, Azizi M, et al; BaxHTN Investigators. N Engl J Med. 2025 Oct 9;393(14):1363- 1374. doi: 10.1056/NEJMoa2507109 LIRE

Revues

• Benefit-harm trade-offs of intensive blood pressure control versus standard blood pressure control on cardiovascular and renal outcomes: an individual participant data analysis of randomised controlled trials.Guo X, et al; BPRULE Study Group.Lancet. 2025 Sep 6;406(10507):1009-1019. doi: 10.1016/S0140-6736(25)01391-1. LIRE
• Overcoming Barriers to Developing and Implementing Novel Therapies for Hypertension. Krychtiuk KA, et al. Hypertension. 2025 Oct;82(10):1599-1611. doi: 10.1161/HYPERTENSIONAHA.125.24992. LIRE
• Clinical staging to guide management of metabolic disorders and their sequelae: a European Atherosclerosis Society consensus statement. Romeo S, et al; European Atherosclerosis Society Consensus. Eur Heart J. 2025 Oct 7;46(38):3685-3713. doi:10.1093/eurheartj/ehaf314. LIRE
• Primary Aldosteronism: An Endocrine Society Clinical Practice Guideline. Adler GK,et al. J Clin Endocrinol Metab. 2025 Aug 7;110(9):2453-2495. doi: 10.1210/clinem/dgaf284 LIRE

Post-hoc analyses of clinical trials

• Effects of Intensive Blood Pressure Control in Patients With Frailty: A Post Hoc Analysis From ESPRIT. Li S, et al; ESPRIT Investigators. J Am Coll Cardiol. 2025 Oct 15:S0735-1097(25)07783-6. doi: 10.1016/j.jacc.2025.08.092. LIRE
• Systolic Blood Pressure Time in Target Range and Acute Kidney Injury in Patients With Hypertension. Chen WH, et al. Hypertension. 2025 Oct 9. doi: 10.1161/HYPERTENSIONAHA.125.25511. LIRE

Etudes observationnelles

• Contemporary Burden of Cardiovascular Disease in Pregnancy: Insights From a Real-World Pregnancy Electronic Health Record Cohort. Lau ES, et al. Circulation. 2025 Oct 14;152(15):1044-1055. doi: 10.1161/CIRCULATIONAHA.125.074692. LIRE
• Shiny and Mobile Apps for Estimating Blood Pressure Percentiles in Children. Montelisciani L, et al. Hypertension. 2025 Oct 1. doi: 10.1161/HYPERTENSIONAHA.125.25087. LIRE
• Prescription Trends of Hydrochlorothiazide vs. Chlorthalidone in the United States (2019-2024). Asante R, et al. Am J Hypertens. 2025 Sep 23:hpaf190. doi: 10.1093/ajh/hpaf190. LIRE
• Poor Accuracy of Blood Pressure Measurement Images Online: Implications for Public Health Education. Aminde LN, et al. Hypertension. 2025 Sep 8. doi: 10.1161/HYPERTENSIONAHA.125.25064 LIRE
• Association Between Migraine and Hypertension in 2 Million Adolescents. Akavian I, et al. Hypertension. 2025 Sep 4. doi: 10.1161/HYPERTENSIONAHA.125.24861. LIRE

• La France à l’honneur: essai RETREAT-FRAIL Reduction of Antihypertensive Treatment in Nursing Home Residents. Benetos A, et al. Published on August 29, 2025, at NEJM.org. DOI: 10.1056/NEJMoa2508157. LIRE
• Nouvelles recommandations US, AC/AHA dans l’HTA publiées conjointement dans Circulation et Hypertension 2025 AHA/ACC/AANP/AAPA/ABC/ACCP/ACPM/AGS/AMA/ASPC/NMA/PCNA/SGIM Guideline for the Prevention, Detection, Evaluation and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Jones DW, et al. Circulation. 2025 Aug 14. doi: 10.1161/CIR.0000000000001356 LIRE
• Nouvelle recommandation : 2025 ESC Guidelines for the management of cardiovascular disease and pregnancy LIRE
• Efficacy and Safety of Baxdrostat in uncontrolled and resistant hypertension. Flack JM et al. N Engl J Med 2025 Aug 30. doi: 10.1056/NEJMoa2507109. Online ahead of print LIRE
• Efficacy and safety of sacubitril/valsartan in Afro-descendant patients with resistant hypertension: a randomized controlled trial. Bitar YSL, et al. J Hypertens. 2025 Sep 1;43(9):1485-1491. doi: 10.1097/HJH.0000000000004075 LIRE
• Blood pressure-lowering efficacy of antihypertensive drugs and their combinations: a systematic review and meta-analysis of randomised, double-blind, placebo-controlled trials. Wang N, et al. Lancet. 2025 Aug 30;406(10506):915-925. doi: 10.1016/S01406736(25)00991-2 LIRE

• Subclinical Primary Aldosteronism and Major Adverse Cardiovascular Events: A Longitudinal Population-Based Cohort Study Goupil R, et al. Circulation. 2025 Jul 9:10.1161/CIRCULATIONAHA.124.073507. PMID: 40631720. LIRE
• Long-term prediction of blood pressure reduction after renal denervation for arterial hypertension, Sagmeister P, at al. J Hypertens. 2025 Jul 7. PMID: 40621832 LIRE
• Lorundrostat in Participants With Uncontrolled Hypertension and Treatment-Resistant Hypertension: The Launch-HTN Randomized Clinical Trial, Saxena M, et al; Launch-HTN Investigators. JAMA. 2025 Jun 30:e259413. PMID: 40587141 LIRE
• Adrenalectomy Versus Medical Therapy in Primary Aldosteronism: A Meta-Analysis of Long-Term Cardiac Remodeling and Function: Medical Versus Adrenalectomy Treatment Compared in Hyperaldosteronism (MATCH) Study, Marzano L, et al. Hypertension. 2025 Jun 25. PMID: 40557482 LIRE
• Sympathetic Overactivation in the Resistant Hypertensive Phenotype: A Meta-Analysis of Published Studies, Grassi G, et al. Hypertension. 2025 Jun 18;82(8):1346-54. PMID: 40528744 LIRE
• Nocturnal blood pressure: pathophysiology, measurement and clinical implications. Position paper of the European Society of Hypertension, Parati G, et al; ESH Working Group on Blood Pressure Monitoring and Cardiovascular Variability. J Hypertens. 2025 Aug 1;43(8):1296-1318. PMID: 40509714 LIRE

 

• Lorundrostat Efficacy and Safety in Patients with Uncontrolled Hypertension.Laffin LJ, et al; Advance-HTN Investigators. N Engl J Med. 2025 May 8;392(18):1813-1823.Pour en savoir plus : Lire
•  Add-On Treatment With Zilebesiran for Inadequately Controlled Hypertension: The KARDIA-2 Randomized Clinical Trial.Desai AS, et al; KARDIA-2 Study Group. JAMA. 2025 May 28:e256681. Pour en savoir plus :  Lire
• Blood Pressure Lowering Effects of a Novel Long-Acting NPR1 Agonist, XXB750, in Healthy Participants: A Randomized, First-in-Human Clinical Study.He Y, et al. Circulation. 2025 May 27;151(21):1544-1546.  Lire
• Spironolactone vs Amiloride for Resistant Hypertension: A Randomized Clinical Trial. Lee CJ, et al. JAMA. 2025 May 14:e255129. Pour en savoir plus :  Lire
• Establishing Reference Values for Pulse Wave Velocity in Young People.Kodithuwakku V, et al; Youth Vascular Consortium collaborators. Hypertension. 2025 May 14. doi: 10.1161/HYPERTENSIONAHA. Pour en savoir plus:  Lire
• Heat extremes and cardiovascular Allied Professions, Association for Acute Cardiovascular Care, European Association of Preventive Cardiology, Heart Failure Association, European Heart Rhythm Association of the ESC, the ESC Council on Hypertension, the ESC Council on Stroke, and the ESC Working Group on Cardiovascular Pharmacotherapy.Chaseling GK, et al. Eur Heart J. 2025 Jun 3:ehaf326. Pour en savoir plus  Lire
• Priorities for Research on Hypertension Care Delivery: A WHO Report Executive Summary. Matsushita K, et al. Hypertension. 2025 Jun;82(6):971-976. doi: 10.1161/HYPERTENSIONAHA.125.24702. PMID: 40109247 Pour en savoir plus :  Lire

 

• • Leung AA, et al. Confirmatory Testing for Primary Aldosteronism : A Study of Diagnostic Test Accuracy. Ann Intern Med. 2025 May 6. Lire
  • Messerli FH, Ram CVS, Burnier M. Low-Salt Diet and Thiazide Diuretics. Circulation. 2025 May 6;151(18):1297-1298. doi: 10.1161/CIRCULATIONAHA.125.074388 Lire
  • Li C, et al. Effect of aerobic exercise on endothelial function in hypertensive and prehypertensive 43(5):727-738. doi: 10.1097/HJH.0000000000003980 Lire
  • Sahlin C, et al. Cardiovascular effects after five nights without continuous positive airway pressure for obstructive sleep 43(5):864-870. doi: 10.1097/HJH.0000000000003990 Lire
  • Vahtera V, et al. Incidence of new onset arterial hypertension after metabolic bariatric 43(5):871-879. doi: 10.1097/HJH.0000000000003993 Lire
  • Tamargo J, et al. New pharmacological agents and novel cardiovascular pharmacotherapy strategies in 2024. Eur Heart J Cardiovasc Pharmacother. 2025 May 2;11(3):292-317. doi: 10.1093/ehjcvp/pvaf012 Lire
  • Bonaca MP, et al; STRIDE Trial Investigators. Semaglutide and walking capacity in people with symptomatic peripheral artery disease and type 2 diabetes (STRIDE): a phase 3b, double-blind, randomised, placebo-controlled trial. Lancet. 2025 May 3;405(10489):1580-1593. doi: 10.1016/S0140-6736(25)00509-4 Lire